Department of Biochemistry and Molecular Biology, College of Medicine, University of Florida, Gainesville, Florida 32610, United States.
Department of Pharmaceutical Sciences and Moulder Center for Drug Discovery Research, Temple University School of Pharmacy, 3307 N Broad Street, Philadelphia, Pennsylvania 19140, United States.
J Med Chem. 2020 Nov 12;63(21):13064-13075. doi: 10.1021/acs.jmedchem.0c01390. Epub 2020 Oct 21.
This study provides a structure-activity relationship study of a series of lipophilic carbonic anhydrase (CA) inhibitors with an acetazolamide backbone. The inhibitors were tested against the tumor-expressed CA isozyme IX (CA IX), and the cytosolic CA I, CA II, and membrane-bound CA IV. The study identified several low nanomolar potent inhibitors against CA IX, with lipophilicities spanning two log units. Very potent pan-inhibitors with nanomolar potency against CA IX and sub-nanomolar potency against CA II and CA IV, and with potency against CA I one order of magnitude better than the parent acetazolamide were also identified in this study, together with compounds that displayed selectivity against membrane-bound CA IV. A comprehensive X-ray crystallographic study (12 crystal structures), involving both CA II and a soluble CA IX mimetic (CA IX-mimic), revealed the structural basis of this particular inhibition profile and laid the foundation for further developments toward more potent and selective inhibitors for the tumor-expressed CA IX.
本研究对一系列以乙酰唑胺为骨架的亲脂性碳酸酐酶(CA)抑制剂进行了构效关系研究。这些抑制剂针对肿瘤表达的 CA 同工酶 IX(CAIX)以及胞质 CA I、CA II 和膜结合 CA IV 进行了测试。研究鉴定了几种针对 CAIX 的低纳摩尔强效抑制剂,其亲脂性跨越两个对数单位。本研究还鉴定了对 CAIX 具有纳摩尔效力、对 CA II 和 CA IV 具有亚纳摩尔效力、对 CA I 的效力比母体乙酰唑胺高一个数量级的强效泛抑制剂,以及对膜结合 CA IV 具有选择性的化合物。一项全面的 X 射线晶体学研究(12 个晶体结构),涉及 CA II 和可溶性 CA IX 模拟物(CA IX-mimic),揭示了这种特殊抑制谱的结构基础,并为进一步开发针对肿瘤表达的 CAIX 的更有效和选择性抑制剂奠定了基础。